Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

March 31, 2019

Conditions
Rhinitis, Allergic
Interventions
DRUG

ALK Alutard birch or 5-grasses

3 injections with 4-5 weeks interval.

DRUG

ALK diluent

0,3% human albumin

Trial Locations (3)

501 82

Allergy Unit, Södra Älvsborgs Hospital, Borås

205 02

ENT department, Skånes University Hospital Malmö and Lund, Malmo

141 86

ENT department, Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Karolinska University Hospital

OTHER

collaborator

Skane University Hospital

OTHER

collaborator

Sodra Alvsborgs Hospital

OTHER

lead

Karolinska Institutet

OTHER

NCT02679105 - Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy | Biotech Hunter | Biotech Hunter